Navigation Links
YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS
Date:5/14/2009

with nimotuzumab worldwide to date, no Grade IV incidents of radiation dermatitis have been described, severe rash has not been observed and reports of the other severe side-effects that are typical of EGFR-targeting molecules have been rare. Nimotuzumab is licensed to YM's majority-owned subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology. YM is developing AeroLEF for the treatment of moderate to severe acute pain. The product is differentiated from other approaches using fentanyl because patients can individually control the analgesia required for their differing intensities of pain. AeroLEF met all endpoints in a randomized Phase II trial and is currently being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various partners will complete their respective clinical tri
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Frost & Sullivan Awards Precision Biosciences for Technology Innovation and Molecular Design Process in the Genomics Market
2. Neurocrine Biosciences to Present at the Deutsche Bank 34th Annual Health Care Conference
3. MichBio Leader Cites New Senate Biosciences Task Force and House Subcommittee as Evidence of States Growing Awareness of Industrys Economic Importance
4. Neurocrine Biosciences Reports First Quarter 2009 Results
5. Sangamo BioSciences Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research
6. Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species
7. ImQuest BioSciences and Arisyn Therapeutics Announce Strategic Partnership to Develop Infectious Disease and Cancer Drugs
8. LaVoie Group Selected by Vaccine Developer, Profectus BioSciences, as Agency of Record
9. Former GE Healthcare Director, Per Foss Appointed CEO for HUNT Biosciences
10. Sangamo BioSciences Announces First Quarter 2009 Conference Call and Webcast
11. Cell Biosciences Launches Next-Generation Protein Characterization System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... , May 20, 2015  Marc Tessier-Lavigne, president ... gift of $100 million from The Marie-Josée and ... new laboratory building that will be the centerpiece ... Marie-Josée and Henry R. Kravis Research Building, two ... Drive, spanning approximately three city blocks following the ...
(Date:5/20/2015)... 20, 2015  Cypher Genomics, Inc., a leading ... Celgene Corporation to apply Cypher,s Coral TM ... with patient response to innovative medicines. The information ... accelerate patient access to the right medicine at ... and development and potentially inform new companion diagnostics.  ...
(Date:5/20/2015)... 19, 2015 Research and Markets ... the "Bone Morphogenetic Proteins Market (Types : ... and Oral - Maxillofacial) - Global Industry Analysis, ... 2022" report to their offering. ... based on the types of recombinant BMPs, applications, ...
(Date:5/20/2015)... Park, CA, Mulhouse, France, Cambridge, MA (PRWEB) May ... leading provider of high quality transporter assay services ... Safety and Pharmacology, and Rhenovia Pharma, a world ... on neurotransmission using Translational Quantitative Systems Pharmacology supported ... a partnership agreement. , The agreement allows both ...
Breaking Biology Technology:The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 4Cypher Genomics Collaborates with Celgene Corporation to Identify Novel Genomic Biomarkers 2Global Bone Morphogenetic Proteins Market Industry Analysis 2014 - 2022 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 3
... Ltd. (Amex: CPD ) announced the resignation as ... the appointment as a Director of the,Company of Gurpartap ... of the Company, effective July 22, 2008., Prior ... in July 2007, Mr. Singh served as Vice President ...
... 23 /PRNewswire-FirstCall/ - Chromos Molecular,Systems Inc. ("Chromos" or ... similar regulatory authorities in the Provinces,of British Columbia, ... trade orders against the Company effective July 22, ... trade orders outstanding against the,Company., The Company ...
... 23 In a video interview, new CEO,Andrew Witty comments ... his strategic vision for the business., ... a diversified global business - Deliver more products of ... podcast and vodcast are available now on, http://www.cantos.com . It,s ...
Cached Biology Technology:Caraco Pharmaceutical Laboratories, Ltd. Announces Resignation from Board of Directors of Jitendra Doshi and Appointment of GP Singh Sachdeva 2Chromos Announces Full Revocation of Cease Trade Orders 2
(Date:4/14/2015)... , April 14, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... for the 2015 New York Design Awards under the ... New York City Design Awards are part of a ... over 2,500 ratings from the marketplace, industry and judging ...
(Date:4/10/2015)... 10, 2015 Research and Markets ... "Security Competitive Profiles - NEC" report to ... NEC will continue to supply a range of ... with a company focus on the development of a ... Winning opportunities in the Asia-Pacific ...
(Date:4/6/2015)... 6, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, ... 62/143028 for MINIATURE, MULTI-PURPOSE ANTENNA METHOD AND ... NXT-ID introduces a new revolutionary method and ... the use of miniature antenna modules for multiple ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... a herpes virus invades cells has remained a mystery to ... funded by the National Institutes of Health and published online ... Biology reveals the unusual structure of the protein complex ... map of a key piece of the herpes virus "cell-entry ...
... that revolutionized gynecologic and urologic surgery in the past decade ... of their diseased thyroid gland without the hallmark neck incision, ... Adam,s apple and controls the body,s metabolic rate, is about ... more than double its size. Dr. David Terris, Porubsky professor ...
... Investigators at the Translational Genomics Research Institute (TGen) have discovered ... longer respond to conventional chemotherapy. A scientific paper that ... Gynecologic Oncology describes how the inhibition of a ... therapies for women with ovarian cancer. The research led ...
Cached Biology News:Map of herpes virus protein suggests a new drug therapy 2Robots preclude neck incision for thyroid surgery 2TGen finds protein inhibitor revives chemotherapy for ovarian patients 2TGen finds protein inhibitor revives chemotherapy for ovarian patients 3
Mouse monoclonal antibody to RAD51L3 - RAD51-like 3 (S. cerevisiae)...
Mouse monoclonal [34B12] to Nop5p + Nop58p - Nucleolar Marker ( Abpromise for all tested applications)....
... Protein A and Protein G bind specifically ... Protein A and Protein G conjugates are ... immunoglobulins (antibodies) and immunoglobulin subtypes from serum, ... other biological fluids. These reagents are also ...
... Optically clear dishes with stacking feature for ... new product number, created to easily match Cornings ... order under the old Sigma-Aldrich number (Z70,947-6) or ... low binding surface Comp Dim: surface area 55 ...
Biology Products: